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Abstract
AIM: To study the individual effects of glucocorticoid 
(GC) therapy on the state of immune activation in 
patient serum.
METHODS: We developed a novel assay in which 
the effect of corticosteroid-treated patient serum on 
healthy donor peripheral blood mononuclear cells 
(target cells) was studied, with a panel of markers for 
effector [interferon (IFN)γ and interleukin (IL)-5] and 
regulatory T cells (FOXP3 and glucocorticoid-induced 
tumor necrosis factor receptor, GITR). The study group 
comprised 19 children with inflammatory bowel dis-
ease. The individual effect of patient serum on target 
cells was analyzed prior to GC therapy and 2 wk later. 
RESULTS: The effect of GC therapy mediated by 
patient serum was seen as a decrease in the target 
cells expression of regulatory T-cell-related markers 
GITR (median suppression 24%, range of suppression 
1%-63%, in 2 cases increase of 6% and 77%, P  < 0.01 
for mitogen-activated target cells) and FOXP3 (median 
suppression 33%, range of suppression 0%-79%, in one 
case an increase of 173%, P  < 0.05 for resting cells), 
and secretion of IFNγ [from a mean of 87 700 pg/mL (SD 
33 900 pg/mL) to 60 900 pg/mL (SD 44 200 pg/mL) in 
mitogen-activated target cells, 13 of the cases showed 
a decrease, P  < 0.01]. The total or weight-related pred-
nisolone dose did not correlate with the patient-serum-
induced changes in the target cell markers.
CONCLUSION: GC response could be monitored at an 
individual level by studying the effect of patient serum 
on signaling pathways of target immune cells.
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
Since the description of  the life-saving effect of  glu-
cocorticoids (GCs) in the treatment of  inflammatory 
bowel disease (IBD), GCs have been the mainstay in 
the treatment of  moderate and severe forms of  the dis-
ease[1]. Although widely used, several patients show an 
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inadequate response to GCs, a phenomenon that could 
not have been foreseen. In patients with GC resistance, 
therapeutic effect is lacking. Those considered to be 
steroid-dependent benefit from the treatment but their 
disease flares up immediately after lowering the GC dose 
or discontinuation of  the therapy. Among IBD patients, 
up to 31%-45% seem to become steroid-dependent[2-4]. 
Other treatment options have not overcome the need for 
GCs in IBD, a disease that is constantly on the increase 
in many western countries[5,6].
The pathogenesis of  IBD is multifactorial. An inappro-
priate response of  a mucosal immune system to the indig-
enous flora and luminal antigens plays a key role that leads 
to activation of  innate immune cells that direct the effector 
and regulatory T-cell responses of  adaptive immunity[7]. 
GC action is mediated by a GC-receptor complex 
that is translocated into the nucleus. The genomic ac-
tions are classified as transrepression, that is, inhibition 
of  the synthesis of  the regulatory proteins, which results 
from the interaction between the activated GC-receptor 
complex and transcription factors, such as nuclear 
factor-κB or activator protein-1, and transactivation, that 
is, induction of  the synthesis of  regulatory proteins  that 
leads to downregulation of  inflammatory cytokines, such 
as tumor necrosis factor-α, interleukin (IL)-12 and in-
terferon (IFN)γ, and upregulation of  anti-inflammatory 
cytokines, such as IL-10, and transforming growth factor 
β[8-11]. GCs have also non-genomic interactions with cel-
lular membranes[12].
Therapeutic response to GCs at an individual level 
is unpredictable. Here, we searched for new means to 
monitor the stage of  immune activation during GC ther-
apy. We developed a novel assay, in which the effect of  
patient serum on donor peripheral blood mononuclear 
cells (PBMCs) was studied using a panel of  markers for 
effector (IFNγ and IL-5) and regulatory T cells (FOXP3 
and glucocorticoid-induced tumor necrosis factor recep-
tor, GITR). We found that attenuation of  inflammation 
during GC therapy was reflected in these markers. 
MATERIALS AND METHODS
Subjects
Nineteen consecutive pediatric patients with active IBD 
(Table 1) were prospectively introduced to oral predniso-
lone (Leiras, Finland), with a constant once daily dose 
of  1 mg/kg (range 15-60 mg) for 2 wk, as described in 
detail elsewhere[13,14]. The need for GCs was based on the 
physician’s global assessment of  severe disease. After the 
2-wk study protocol[13,14], the clinicians tapered the GC 
dose and adjusted the therapy. At the start of  GC ther-
apy, the maintenance therapies (Table 1) were unaltered. 
All patients had undergone gastrointestinal endoscopy to 
establish the diagnosis of  IBD[15]. 
Blood samples
The first blood sample was taken prior to the first GC 
dose on the day that the clinician instructed the start of  
GC therapy. The second sample was taken after 2 wk 
and the two samples were compared individually. Rou-
tine samples for blood count, hemoglobin, erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP) 
were obtained at the start of  GC therapy and after 2 wk.
Laboratory assay 
PBMCs and the plasma from the blood of  healthy 
donors and patients were separated by Ficoll-Paque 
(Amersham Biosciences, Freiburg, Germany) centrifu-
gation according to the protocol of  the manufacturer. 
PBMCs were suspended in 1 mL of  medium (RPMI 
with HEPES buffer (Gibco, Carlsbad, CA, USA) with 
0.002 mmol/L glutamine (Gibco), 25 µL/mL gentami-
cin (Gibco) and 5% serum), for counting. PBMCs were 
frozen at -136℃ with DMSO (Sigma-Aldrich Corp, St. 
Louis, MO, USA). These cells from healthy donors were 
used as target cells. Target cells were diluted in cell cul-
ture medium (described above) without serum. Target 
cells, unactivated or activated with phytohemagglutin 
(PHA, 5 µg/mL) were cultured as duplicates in the pres-
ence of  the IBD patients’ inactivated (56℃ for 35 min) 
serum, at a concentration of  8%, for 72 h at 37℃ in a 
humidified atmosphere with 50 mL/L CO2. After cul-
ture, the supernatants and target cells were collected by 
centrifugation at 400 g for 7 min. RT lysis buffer (Sigma-
Aldrich) was added to the target cells, and the superna-
tants were stored at -70℃. The target cell assay was re-
peated using PBMCs from two different healthy donors 
(26-year-old woman and 31-year-old man) as target cells. 
Results represent one series of  experiments.
ELISA for IFNγ and IL-5
IL-5 and IFNγ were measured with ELISA in duplicate 
from the supernatants collected from the target cell cul-
tures incubated in the presence of  patient serum. IFNγ 
and IL-5 were detected as described previously[16,17]. We 
subtracted the non-stimulated value from the stimulated 
value to obtain the ∆ value for statistical analysis.
Quantitative reverse transcriptase-polymerase chain 
reaction (RT-PCR)
Total RNA was isolated from cell samples with GenElute 
Mammalian total RNA Miniprep kit (Sigma-Aldrich), and 
RNA concentration was measured by a spectrophotome-
ter (ND-1000; NanoDrop Technologies Inc, Wilmington, 
DE, USA). Reverse transcription was performed by using 
TaqMan Reverse Transcription reagents (Applied Biosys-
tems, Foster City, CA, USA), with additional treatment of  
total RNA at 10 ng/µL with DNAse I (0.01 U/µL) (Roche 
Diagnostics, Mannheim, Germany) to eliminate genomic 
DNA. Quantitative RT-PCR was performed using pre-
designed FAM-labeled TaqMan Gene Expression Assay 
reagents (Applied Biosystems) and the ABI Prism 7700 
Sequence Detection System (Applied Biosystems) in trip-
licate wells. Assay reagents for FOXP3 (Hs00203958_m1), 
GATA3 (Hs00231122_m1), T-BET (Hs00203436_m1), 
GITR (Hs00188346_m1), IFNγ (Hs00174143_m1), IL-5 
(Hs00542562_m1), IL-10 (Hs00174086_m1), STAT-5b 
(Hs00273500_m1), and 18s RNA (Hs99999901_s1) were 
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used. The quantitative value obtained from the TaqMan 
run was the threshold cycle Ct, which indicated the num-
ber of  PCR cycles at which the amount of  amplified tar-
get molecule exceeded a predefined fluorescence thresh-
old value. The difference value (∆Ct) was the normalized 
quantitative value of  the expression level of  the target 
gene, which was achieved by subtracting the Ct value of  
the housekeeping gene (18S) from that of  the target gene. 
An exogenous cDNA pool calibrator was collected from 
PHA-stimulated PBMCs, and considered as an interassay 
standard to which normalized samples were compared. 
∆∆Ct was the difference between the ∆Ct of  the analyzed 
sample and that of  the calibrator. Calculation of  2-∆∆Ct 
gave a relative amount of  the target gene in analyzed 
sample compared with the calibrator, both normalized to 
an endogenous control (18S). For presentations, the rela-
tive amount of  target genes was multiplied by 1000 and 
expressed as relative units. When fold change of  gene 
expression following GC therapy was expressed, it was 
calculated by dividing the relative expression after therapy 
by that before therapy. For test reliability, those samples 
with mRNA expression under 10 ng/µL (n = 14 for rest-
ing and n = 1 for activated target cells) between triplicate 
wells were excluded from the statistical analysis.
Statistical analysis
We used the Wilcoxon rank test, two-tailed Mann-Whit-
ney U test, two-tailed Spearman’s rho correlation test, 
and χ2 test when appropriate (SPSS version 13.0). In the 
few cases with IFNγ greater than the detection limit of  
120 000 pg/mL, this high value was used in statistical 
analysis. P < 0.05 was set for statistical significance.
Ethics
The study was approved by the Ethics Committee of  
Helsinki University Central Hospital and by the Institu-
tional Review Board. The families attending the study 
signed an informed consent form.
RESULTS
Serum-induced changes in gene expression of target 
cells
The median expression of  FOXP3-specific mRNA in 
the resting target cells was suppressed by 33% (range 
of  suppression 0%-79%, in one case, an increase of  
173%, P < 0.05) and the median expression of  GITR-
specific mRNA by 46% (range 2%-78%, in three cases, 
an increase of  6%-124%, P = 0.050), when the effect 
of  serum after GC was compared to that before therapy 
(Figure 1). In PHA-activated target cells, the median 
expression of  GITR-specific mRNA was suppressed 
by 25% compared to the pre-treatment serum (range 
of  suppression 1%-63%, in two cases, an increase of  
6%-77%, P < 0.01). 
The total or weight-related prednisolone dose did not 
correlate with the serum-induced GITR or FOXP3 gene 
expression of  the target cells.
Serum-induced changes in secretion of IFNγ and IL-5 
from target cells
IFNγ secretion from target cells was lower when cul-
tured with patient serum taken 2 wk after the start of  
GC therapy, compared to the culture with the serum 
sample taken before GC therapy. This decrease was seen 
in resting target cells [from a mean of  68 pg/mL (SD 
110 pg/mL) to 1.5 pg/mL (SD 6.7 pg/mL); however, 
because of  the low secretion of  IFNγ in resting target 
cells, detectable levels were only seen in seven cases, 
six of  whom showed a decrease, P < 0.05]. In activated 
target cells, 13 cases showed a decrease from a mean 
of  87 700 pg/mL (SD 33 900 pg/mL) to 60 900 pg/mL 
1106 March 7, 2010|Volume 16|Issue 9|WJG|www.wjgnet.com
Table 1  Clinical characteristics of 19 children with IBD treated with oral prednisolone
Patient No. Age (yr) Sex Diagnosis Disease extension at 
diagnosis




1 14 Male UC Left-sided 2.9 5-ASA
2 14 Female UC Pancolitis 0.2 5-ASA
3      5.6 Female UC Distal 0.8 No
4 18 Male UC Pancolitis 5.6 5-ASA
5 17 Male UC Pancolitis 2.2 5-ASA
6 15 Female UC Pancolitis                     3 5-ASA
7 15 Male UC Pancolitis 0.8 5-ASA
8 14 Male UC Pancolitis 0.1 5-ASA
9 14 Male UC Pancolitis                     0 5-ASA
10 13 Female UC Pancolitis 3.7 5-ASA, AZA
11 12 Male UC Pancolitis                     0 5-ASA
12 12 Male UC Pancolitis                     0 5-ASA
13 12 Female UC Pancolitis 1.3 5-ASA
14      9.4 Male UC Pancolitis 4.2 5-ASA
15      7.4 Male UC Pancolitis 1.8 5-ASA
16      7.2 Male UC Pancolitis 1.3 5-ASA
17 15 Male CD Pancolitis                     0 5-ASA
18 12 Female CD Pancolitis                   10 5-ASA
19 16 Male IC Pancolitis 1.2 5-ASA
IBD: Inflammatory bowel disease; 5-ASA: 5-aminosalicylic acid; AZA: Azathioprine; IC: Indeterminate colitis; UC: Ulcerative colitis.
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(SD 44 200 pg/mL) (P < 0.01, Table 2). The decrease in 
serum-induced IL-5 secretion from activated target cells 
decreased after GC therapy was close to the level of  
statistical significance [from a mean of  60 pg/mL (SD 
50 pg/mL) to 32 pg/mL (SD 46 pg/mL); 12 cases 
showed a decrease, P = 0.055, Table 2]. Serum-induced 
IL-5 secretion from resting target cells was undetectable. 
The total or weight-related prednisolone dose did not 
correlate with IFNγ or IL-5 secretion from target cells. 
Changes of cytokines and transcription-factor-specific 
mRNA in patient PBMCs 
There were no statistically significant changes in the 
mRNA levels of  the cytokines IFNγ, IL-5 and IL-10, or 
the transcription factors FOXP3, GITR, GATA3, STAT-
5b and T-bet, in PBMCs derived from patients with IBD 
before and after 2 wk of  GC therapy.
ESR, CRP and leukocyte count
ESR decreased from a median of  29 (range 0-64) mm/h 
to 12 (range 4-36) mm/h (P < 0.01), and CRP decreased 
from a median of  10 (range 5-75) mg/L to 5 (range 
5-10) mg/L (P < 0.01) during 2 wk GC therapy. ESR or 
CRP did not correlate with the expression of  GITR or 
FOXP3 from target cells, or with IFNγ or IL-5 secretion 
from target cells. 
DISCUSSION
We found that serum from a GC-treated patient modu-
lated in vitro the response of  healthy donor-derived 
PBMCs and simulated the effects of  GC treatment on 
the patient immune system. The attenuation of  systemic 
inflammation during GC therapy was demonstrated with 
this assay at an individual level. The effect of  GC treat-
ment was mediated by patient serum, which caused a de-
crease in the target cell expression of  regulatory T-cell-
associated markers GITR[18] and FOXP3[19], and in the 
secretion of  Th1 cytokine IFNγ. 
The serum-induced decrease in cytokine and signaling 
molecule expression in the target cells was not attributed 
to the GC dose. This suggests that the observed changes 
in the levels of  cell signaling markers were not solely due 
to GCs, but rather reflected the net systemic effect in 
patient serum. It has been reported previously that nei-
ther the level of  GC in plasma or serum or serum GC 
bioactivity correlate with therapeutic responses[14,20,21]. To 
study whether serum-induced effects on target cells were 
mediated by GC receptors, we co-cultured the target cells 
with patient serum and GC receptor antagonist mifepris-
tone[13,22]. Disappointingly, the results were uninformative 
as the GC receptor antagonist suppressed the target cell 
cytokine production and the treatment-mediated effects 
could not be assessed (data not shown).
It is highlighted that we did not see any direct effects 
of  GC therapy on PBMCs derived from the patients. 
The PBMC population is heterogeneous and comprises 
naïve and memory T cells and effector and regulatory 
T cells. Thus, the net effect of  GCs might be covered 
when studied in patient-derived PBMCs. Instead, we 
found that the effect of  GC treatment was demonstrat-
ed as a patient-serum-induced decrease of  FOXP3 and 
GITR in the target cells.
Earlier studies of  the effect of  GC therapy have fo-
cused on the direct changes induced in patient PBMC or 
lymphocyte subtypes such as regulatory T cells. The ob-
servation of  GC-induced changes in regulatory T-cell-re-
lated FOXP3 is controversial, and there are no data from 
pediatric IBD. In an in vitro study on regulatory T cells 
of  healthy donors, the administration of  dexamethasone 
on purified CD4+ T cells induced a transient increase in 
the expression of  FOXP3[23]. Accordingly, in asthmatic 
patients, an increase in FOXP3 mRNA expression has 
been observed in freshly isolated and purified CD4+ T 
cells after oral GC administration[23]. However, in another 
study, the counts of  FOXP3-expressing CD4+CD25high 
T cells and mRNA expression of  GITR in PBMCs were 




















Figure 1  GITR and FOXP3 gene expression in target cells when cultured 
with patient serum taken before (A) and 2 wk after (B) GC therapy. For 
test reliability, the patients with low mRNA expression < 10 ng/µL (n = 7) were 
excluded from the Figure and the statistical analyses. aP < 0.05, bP = 0.050.
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Patient No. IFNγ A PHA IFNγ B PHA IL-5 A PHA IL-5 B PHA
1   7200 19 000 11 28
2 99 000   8500      0.0      0.0
3 41 000 12 000 77 19
4 82 000 17 000         150      9.3
5 94 000 36 000         150 11
6   > 120 000   > 120 000 54 21
7   > 120 000      100 000         140 38
8 63 000 28 000      1.2      1.2
9 59 000 34 000 99 34
10      110 000      120 000 75 89
11   > 120 000 84 000      8.1      1.2
12   > 120 000 85 000 12      3.5
13 91 000 19 000 84 17
14 40 000 62 000 73         130
15 91 000   6600 10      7.2
16   > 120 000   > 120 000 15      2.3
17 90 000 63 000 69 33
18   > 120 000 97 000 33      0.0
19 68 000      120 000 89         160
Table 2  Concentration of IFNγ and IL-5 (pg/mL)
Measured with ELISA in the supernatants of healthy donor PBMCs (target 
cells, stimulated with PHA) cultured with patient serum taken before (A) 
and 2 wk after oral GC therapy (B).
unaltered after 4 wk treatment with inhaled steroids[24]. 
Furthermore, in a study of  patients with allergic rhinitis, 
FOXP3-positive cells from nasal mucosa biopsies de-
creased significantly after several weeks treatment with 
intranasal GCs[25]. These controversial findings of  regu-
latory T-cell activation in different tissues and during dif-
ferent courses of  GC therapy underline the importance 
of  further studies to increase our understanding of  the 
anti-inflammatory effects of  GCs. 
In line with our finding of  a decrease in target cell 
IFNγ secretion, downregulation of  pro-inflammatory 
cytokines, including IFNγ, has been reported in an in vitro 
study using PBMCs from healthy donors stimulated with 
dexamethasone and studied with DNA microarray chip 
analysis, online PCR and flow cytometry[26]. 
Recently, it has been shown that, in severe pediatric 
colitis, the response to intravenous GC could be pre-
dicted already on day 3, with the aid of  clinical activity 
scores[27]. However, for oral GC therapy, there are no 
such data. We assessed the immunological responses of  
our patients at 2 wk, a time interval that was initially cho-
sen for practical reasons. Therefore, it warrants further 
study to investigate if  our findings could be detected 
during the first week of  GC therapy. 
To conclude, we developed a new cell culture assay to 
study the effect of  GC therapy at an individual level, us-
ing serum samples taken from patients during GC thera-
py. We consider that the patient-serum-induced changes 
in the target cells reflect the net effect of  the metabolism 
of  GC and its immunological effects, and this mirrors 
the systemic inflammatory activity of  the disease in the 
patient’s circulation during GC therapy.
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Background
Corticosteroids are widely used in the treatment of several diseases, for 
example, asthma, rheumatic disease and inflammatory bowel disease (IBD). 
Corticosteroids are effective in suppressing active inflammation but not all 
patients respond to treatment, and various side effects are common. To date, 
the therapeutic effect cannot be foreseen and there are no specific means to 
monitor the therapeutic response at an early phase of the treatment.  
Research frontiers
IBD is a chronic disorder with an increasing incidence in children. In pediatric 
patients, the disease course is often aggressive and the majority of patients 
need corticosteroids to suppress their symptoms. There is an urgent need for 
new means to monitor therapeutic responses to improve patient care.   
Innovations and breakthroughs
The authors describe a novel assay that gives the possibility to monitor 
therapeutic responses to corticosteroids, using a serum sample from the 
patient. Disease activity is reflected in the serum that is used in an in vitro cell 
assay to stimulate human white blood cells. In cell culture, it is possible to 
measure how the effect of patient serum on specific white blood cell markers (T 
cells) varies according to the given therapy. With this novel assay, it is possible 
to study the individual effect of corticosteroid therapy.
Applications
The results suggest that the effect of corticosteroid therapy on disease activity 
can be measured from patient serum at an early phase of the therapy. The 
authors studied pediatric patients with IBD, and further study is warranted 
to establish whether this kind of method is suitable for other patients with 
corticosteroid treatment. 
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